78 related articles for article (PubMed ID: 16362868)
1. Could Paclitaxel-eluting stents be superior to sirolimus-eluting stents for the treatment of saphenous vein graft lesions?
Brilakis ES; Banerjee S
Am J Cardiol; 2010 Nov; 106(9):1367-8. PubMed ID: 21029842
[No Abstract] [Full Text] [Related]
2. Drug-eluting stents.
Whitlow P
J Invasive Cardiol; 2004 Jul; 16(7 Suppl):2S-6S. PubMed ID: 23573564
[TBL] [Abstract][Full Text] [Related]
3. Clinical outcome of B2/C type isolated proximal LAD disease treated with drug-eluting stents.
Ciçek D; Pekdemir H; Kalay N; Müderrisoğlu H
Anadolu Kardiyol Derg; 2011 Nov; 11(7):648-9. PubMed ID: 21967787
[No Abstract] [Full Text] [Related]
4. Everolimus-eluting stents: insights from the SPIRIT IV and COMPARE trials.
Kedhi E; Stone GW
Expert Rev Cardiovasc Ther; 2010 Sep; 8(9):1207-10. PubMed ID: 20828341
[No Abstract] [Full Text] [Related]
5. Differential clinical outcomes after 1 year vs. 5 years in the SORTOUT III randomized comparison of zotarolimus- and sirolimus-eluting coronary stents.
Maeng M
Eur Heart J; 2014 Sep; 35(35):2340-1. PubMed ID: 25349884
[No Abstract] [Full Text] [Related]
6. Choosing a drug-eluting stent: how are CYPHER and TAXUS different?
Perin EC
J Invasive Cardiol; 2004 Sep; 16 Suppl F():12F-16F; discussion 18F-21F. PubMed ID: 23573648
[No Abstract] [Full Text] [Related]
7. Is there enough evidence for routine use of drug-eluting stents in acute myocardial infarction with ST segment elevation?
Tesić M; Stanković G
Vojnosanit Pregl; 2014 Sep; 71(9):870-4. PubMed ID: 25282786
[No Abstract] [Full Text] [Related]
8. Treatment of unprotected left main coronary artery stenosis with a drug eluting stent in a heart transplant patient with allograft vasculopathy.
Matos G; Steen L; Leya F
Heart; 2005 Feb; 91(2):e11. PubMed ID: 15657201
[TBL] [Abstract][Full Text] [Related]
9. Carotid and peripheral intervention.
Kapadia SR; Yadav JS
J Invasive Cardiol; 2004 Jul; 16(7 Suppl):50S-53S. PubMed ID: 23573574
[TBL] [Abstract][Full Text] [Related]
10. Prednisone: the last gasp of immunosuppresive therapy for restenosis prevention.
Waksman R; Epstein SE
Eur Heart J; 2013 Jun; 34(23):1702-4. PubMed ID: 23571835
[No Abstract] [Full Text] [Related]
11. Comparison of bare-metal and sirolimus- or paclitaxel-eluting stents for aorto-ostial coronary disease.
Barlis P; Kaplan S; Dimopoulos K; Ferrante G; Di Mario C
Cardiology; 2008; 111(4):270-6. PubMed ID: 18451644
[TBL] [Abstract][Full Text] [Related]
12. Drug-eluting coronary stents: many meta-analyses, little benefit.
Prescrire Int; 2009 Apr; 18(100):70-4. PubMed ID: 19585727
[TBL] [Abstract][Full Text] [Related]
13. Drug-eluting stents: the panacea for restenosis?
Lim MC
Singapore Med J; 2004 Jul; 45(7):300-2. PubMed ID: 15221043
[No Abstract] [Full Text] [Related]
14. [Sirolimus-eluting vs paclitaxel-eluting stents -- the trials confirm differences in clinical outcome].
Gil RJ
Kardiol Pol; 2005 Nov; 63(5):574-6; discussion 577. PubMed ID: 16362868
[No Abstract] [Full Text] [Related]
15. Drug-eluting stents: from randomized trials to the real world.
Saia F; Degertekin M; Lemos PA; Serruys PW
Minerva Cardioangiol; 2004 Oct; 52(5):349-63. PubMed ID: 15514571
[TBL] [Abstract][Full Text] [Related]
16. Understanding the drug-eluting stent trials.
Coolong A; Kuntz RE
Am J Cardiol; 2007 Sep; 100(5A):17K-24K. PubMed ID: 17719349
[TBL] [Abstract][Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
